DK0722722T4 - Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse - Google Patents

Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse

Info

Publication number
DK0722722T4
DK0722722T4 DK95402582T DK95402582T DK0722722T4 DK 0722722 T4 DK0722722 T4 DK 0722722T4 DK 95402582 T DK95402582 T DK 95402582T DK 95402582 T DK95402582 T DK 95402582T DK 0722722 T4 DK0722722 T4 DK 0722722T4
Authority
DK
Denmark
Prior art keywords
treat cutaneous
cutaneous redness
substance antagonist
neurogenic origin
neurogenic
Prior art date
Application number
DK95402582T
Other languages
English (en)
Other versions
DK0722722T3 (da
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0722722(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of DK0722722T3 publication Critical patent/DK0722722T3/da
Publication of DK0722722T4 publication Critical patent/DK0722722T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95402582T 1994-12-19 1995-11-17 Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse DK0722722T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415252A FR2728165A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene

Publications (2)

Publication Number Publication Date
DK0722722T3 DK0722722T3 (da) 1999-06-14
DK0722722T4 true DK0722722T4 (da) 2003-07-07

Family

ID=9469930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95402582T DK0722722T4 (da) 1994-12-19 1995-11-17 Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse

Country Status (15)

Country Link
US (1) US5744156A (da)
EP (1) EP0722722B2 (da)
JP (1) JPH08208508A (da)
AR (1) AR000357A1 (da)
AT (1) ATE171372T1 (da)
BR (1) BR9505381A (da)
CA (1) CA2165518C (da)
DE (1) DE69504949T3 (da)
DK (1) DK0722722T4 (da)
ES (1) ES2124983T5 (da)
FR (1) FR2728165A1 (da)
HU (1) HU218944B (da)
MX (1) MX9505192A (da)
PL (1) PL311917A1 (da)
RU (1) RU2140263C1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
EP0996461B1 (en) * 1997-10-31 2005-01-12 Walter Reed Army Institute of Research Use of a complement activation inhibitor in the manufacture of a medicament for inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
FR2774285B1 (fr) 1998-02-03 2001-06-15 Roche Posay Lab Pharma Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
DE10025553A1 (de) * 2000-05-24 2001-11-29 Merck Patent Gmbh Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
EP1600158A1 (en) * 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
MY177591A (en) 2006-10-16 2020-09-22 Lion Corp Nk1 receptor antagonist composition

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5921656A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd ポリペプチド誘導体
US4472305A (en) 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
US4839465A (en) 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
GB8807921D0 (en) 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Ws-9326 & its derivatives
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0360390A1 (en) † 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991012266A1 (en) 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
PL168236B1 (pl) 1990-05-31 1996-01-31 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL
EP0532527B1 (en) 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DK0498069T3 (da) 1990-12-21 1995-12-04 Fujisawa Pharmaceutical Co Ny anvendelse af peptidderivat
AU652407B2 (en) 1991-01-10 1994-08-25 Pfizer Inc. N-alkyl quinuclidinium salts as substance P antagonists
US5242930A (en) 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
EP0573522B1 (en) 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
EP0581777A1 (en) 1991-03-26 1994-02-09 Pfizer Inc. Stereoselective preparation of substituted piperidines
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
DK0585328T3 (da) 1991-05-22 2002-02-11 Pfizer Substituerede 3-aminoquinuclidiner
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
UA39168C2 (uk) 1991-06-20 2001-06-15 Пфайзер, Інк. Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
TW202432B (da) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) † 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
AU664188B2 (en) † 1991-07-05 1995-11-09 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5472978A (en) 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
WO1993001159A1 (en) † 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
ATE136885T1 (de) 1991-08-20 1996-05-15 Merck Sharp & Dohme Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
DK0607164T3 (da) 1991-09-26 2002-06-17 Pfizer Kondenserede tricykliske nitrogenholdige heterocykliske forbindelser som substans P-receptorantagonister
WO1993009116A1 (en) 1991-11-07 1993-05-13 Yoshitomi Pharmaceutical Industries, Ltd. Quinuclidine compound and medicinal use thereof
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
GB9201179D0 (en) † 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
GB9222486D0 (en) † 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
FR2719474B1 (fr) † 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.

Also Published As

Publication number Publication date
JPH08208508A (ja) 1996-08-13
HU9503625D0 (en) 1996-02-28
RU2140263C1 (ru) 1999-10-27
PL311917A1 (en) 1996-06-24
EP0722722B2 (fr) 2003-03-05
DK0722722T3 (da) 1999-06-14
DE69504949T2 (de) 1999-02-18
MX9505192A (es) 1997-04-30
ATE171372T1 (de) 1998-10-15
ES2124983T3 (es) 1999-02-16
US5744156A (en) 1998-04-28
FR2728165A1 (fr) 1996-06-21
EP0722722B1 (fr) 1998-09-23
BR9505381A (pt) 1997-11-18
HU218944B (hu) 2001-01-29
DE69504949T3 (de) 2004-01-15
FR2728165B1 (da) 1997-02-07
ES2124983T5 (es) 2003-11-16
DE69504949D1 (de) 1998-10-29
AR000357A1 (es) 1997-06-18
CA2165518C (fr) 2002-07-16
CA2165518A1 (fr) 1996-06-20
EP0722722A1 (fr) 1996-07-24
HUT74948A (en) 1997-03-28

Similar Documents

Publication Publication Date Title
DK0734729T4 (da) Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning
DK0722722T4 (da) Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse
DK0925287T3 (da) Heterocykliske metalloproteaseinhibitorer
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
DK0923561T3 (da) Heterocykliske metalloproteaseinhibitorer
DK0970095T3 (da) Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
LV12102A (lv) Rotamazes funkciju inhibitori
DK0722736T3 (da) Topisk sammensætning indeholdende en antagonist for substans P
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
DE69725465D1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
DK1114051T3 (da) Inhibitorer for p38
ATE216997T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE227283T1 (de) Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
DE69824199D1 (de) Lactamverbindungen als metalloprotease-inhibitoren
ATE254106T1 (de) Cycloalkano-pyridine als cetp-inhibitoren
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69728139T2 (de) Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
IS2230B (is) Aukinn stöðugleiki lausna til inndælingar
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
ATE245653T1 (de) Imidazolverbindungen als phosphodiesterase vii- hemmer
ATE210112T1 (de) Substituierte 4-biphenyl-4- hydroxybuttersäurederivate als matrix metallprotease inhibitoren
DE69433141D1 (de) Zusammensetzungen aus kohleteerschlamm
DK1073431T3 (da) Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom
ATE229497T1 (de) Substituierte phenethyl-derivate als matrx- metalloprotease-inhibitoren